"How lipid nanoparticle delivery vectors and prime editing are correcting genetic anomalies directly inside human tissue without viral side effects."
Introduction
First-generation gene therapies required extracting a patient’s stem cells, modifying them in a cleanroom, and transplanting them back. In vivo CRISPR therapeutics edit genetic mutations directly inside living human organs with a single intravenous infusion.
Lipid Nanoparticles (LNPs) and Organ-Specific Targeting
By engineering the surface charge and lipid composition of mRNA delivery nanoparticles, clinicians can direct CRISPR Cas9 editors specifically to hepatocytes in the liver or cardiac tissue, achieving over 90% target gene knockout in clinical trials.
“We are transitioning from managing the chronic symptoms of hereditary diseases to permanently editing the underlying genetic code.”
Prime Editing: Precision Without Double-Strand DNA Breaks
Prime editing combines a modified Cas9 nickase with a reverse transcriptase to rewrite target DNA sequences directly without cutting both DNA strands, eliminating off-target chromosomal translocations.
Key Takeaways
• In vivo therapies edit mutated genes directly inside the body with single infusions.
• Lipid nanoparticles deliver Cas9 machinery without viral vector immunogenicity.
• Prime editing achieves nucleotide substitutions without causing double-strand DNA breaks.
